Cell-based remyelinating therapies in multiple sclerosis

Evidence from experimental studies

Stefano Pluchino, Roberto Furlan, Gianvito Martino

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Purpose of review: Spontaneous remyelination occurs in the central nervous system of patients with multiple sclerosis. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture. The development of cell-based therapies, aimed at promoting multifocal remyelination, is therefore foreseen. Recent findings: Several experimental cell-based strategies aimed at replacing damaged myelin-forming cells have been developed in the last few years. However, most of these therapeutic approaches - although consistently able to form new myelin sheaths at the transplantation site - are unfeasible owing to the mutifocality of the demyelinating process in multiple sclerosis patients and the inability to grow and produce large numbers of differentiated myelin-forming cells in vitro. Stem cell-based therapies that partially overcome these limitations have been proposed recently. Summary: Stem cell-based remyelinating therapies can be considered a plausible alternative strategy in immune-mediated demyelinating disorders. However, before any potential applications in patients with multiple sclerosis can be envisaged, it is necessary to confront the following preliminary, and still unsolved, questions: (1) the ideal stem cell source for transplantation; (2) the most appropriate route of stem cell administration; and, last but not least, (3) the best approach for achieving an appropriate, functional and long-lasting integration of transplanted stem cells into the host tissue.

Original languageEnglish
Pages (from-to)247-255
Number of pages9
JournalCurrent Opinion in Neurology
Volume17
Issue number3
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Myelin Sheath
Multiple Sclerosis
Stem Cells
Cell- and Tissue-Based Therapy
Stem Cell Transplantation
Demyelinating Diseases
Therapeutics
Central Nervous System
Transplantation

Keywords

  • Cell therapy
  • Demyelination
  • Multiple sclerosis
  • Neural stem cells
  • Remyelination
  • Transplantation

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Cell-based remyelinating therapies in multiple sclerosis : Evidence from experimental studies. / Pluchino, Stefano; Furlan, Roberto; Martino, Gianvito.

In: Current Opinion in Neurology, Vol. 17, No. 3, 06.2004, p. 247-255.

Research output: Contribution to journalArticle

@article{7a32122a451b428986ae94c3c86ceff9,
title = "Cell-based remyelinating therapies in multiple sclerosis: Evidence from experimental studies",
abstract = "Purpose of review: Spontaneous remyelination occurs in the central nervous system of patients with multiple sclerosis. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture. The development of cell-based therapies, aimed at promoting multifocal remyelination, is therefore foreseen. Recent findings: Several experimental cell-based strategies aimed at replacing damaged myelin-forming cells have been developed in the last few years. However, most of these therapeutic approaches - although consistently able to form new myelin sheaths at the transplantation site - are unfeasible owing to the mutifocality of the demyelinating process in multiple sclerosis patients and the inability to grow and produce large numbers of differentiated myelin-forming cells in vitro. Stem cell-based therapies that partially overcome these limitations have been proposed recently. Summary: Stem cell-based remyelinating therapies can be considered a plausible alternative strategy in immune-mediated demyelinating disorders. However, before any potential applications in patients with multiple sclerosis can be envisaged, it is necessary to confront the following preliminary, and still unsolved, questions: (1) the ideal stem cell source for transplantation; (2) the most appropriate route of stem cell administration; and, last but not least, (3) the best approach for achieving an appropriate, functional and long-lasting integration of transplanted stem cells into the host tissue.",
keywords = "Cell therapy, Demyelination, Multiple sclerosis, Neural stem cells, Remyelination, Transplantation",
author = "Stefano Pluchino and Roberto Furlan and Gianvito Martino",
year = "2004",
month = "6",
doi = "10.1097/00019052-200406000-00003",
language = "English",
volume = "17",
pages = "247--255",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cell-based remyelinating therapies in multiple sclerosis

T2 - Evidence from experimental studies

AU - Pluchino, Stefano

AU - Furlan, Roberto

AU - Martino, Gianvito

PY - 2004/6

Y1 - 2004/6

N2 - Purpose of review: Spontaneous remyelination occurs in the central nervous system of patients with multiple sclerosis. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture. The development of cell-based therapies, aimed at promoting multifocal remyelination, is therefore foreseen. Recent findings: Several experimental cell-based strategies aimed at replacing damaged myelin-forming cells have been developed in the last few years. However, most of these therapeutic approaches - although consistently able to form new myelin sheaths at the transplantation site - are unfeasible owing to the mutifocality of the demyelinating process in multiple sclerosis patients and the inability to grow and produce large numbers of differentiated myelin-forming cells in vitro. Stem cell-based therapies that partially overcome these limitations have been proposed recently. Summary: Stem cell-based remyelinating therapies can be considered a plausible alternative strategy in immune-mediated demyelinating disorders. However, before any potential applications in patients with multiple sclerosis can be envisaged, it is necessary to confront the following preliminary, and still unsolved, questions: (1) the ideal stem cell source for transplantation; (2) the most appropriate route of stem cell administration; and, last but not least, (3) the best approach for achieving an appropriate, functional and long-lasting integration of transplanted stem cells into the host tissue.

AB - Purpose of review: Spontaneous remyelination occurs in the central nervous system of patients with multiple sclerosis. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture. The development of cell-based therapies, aimed at promoting multifocal remyelination, is therefore foreseen. Recent findings: Several experimental cell-based strategies aimed at replacing damaged myelin-forming cells have been developed in the last few years. However, most of these therapeutic approaches - although consistently able to form new myelin sheaths at the transplantation site - are unfeasible owing to the mutifocality of the demyelinating process in multiple sclerosis patients and the inability to grow and produce large numbers of differentiated myelin-forming cells in vitro. Stem cell-based therapies that partially overcome these limitations have been proposed recently. Summary: Stem cell-based remyelinating therapies can be considered a plausible alternative strategy in immune-mediated demyelinating disorders. However, before any potential applications in patients with multiple sclerosis can be envisaged, it is necessary to confront the following preliminary, and still unsolved, questions: (1) the ideal stem cell source for transplantation; (2) the most appropriate route of stem cell administration; and, last but not least, (3) the best approach for achieving an appropriate, functional and long-lasting integration of transplanted stem cells into the host tissue.

KW - Cell therapy

KW - Demyelination

KW - Multiple sclerosis

KW - Neural stem cells

KW - Remyelination

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=2642516346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642516346&partnerID=8YFLogxK

U2 - 10.1097/00019052-200406000-00003

DO - 10.1097/00019052-200406000-00003

M3 - Article

VL - 17

SP - 247

EP - 255

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 3

ER -